Literature DB >> 14595558

Health economic issues of screening programmes.

Manfred Wildner1.   

Abstract

Economic evaluation supports decision making in health care in view of alternative courses of action and limited resources. It aims at providing maximum benefit in relation to invested resources. In the context of screening, it is required from an economical viewpoint that the cost of case finding, including confirmatory diagnostic tests and treatment, should be economically balanced in relation to possible expenditure on medical care as a whole. Costs of false-positive findings are crucial in newborn screening and pertain to direct costs (e.g. necessary diagnostic work-up), indirect costs (e.g. absence from work of parents) and intangible costs (e.g. anxiety and distress caused, stigmatisation).

Entities:  

Mesh:

Year:  2003        PMID: 14595558     DOI: 10.1007/s00431-003-1341-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  4 in total

1.  Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel.

Authors:  Ralph P Insinga; Ronald H Laessig; Gary L Hoffman
Journal:  J Pediatr       Date:  2002-10       Impact factor: 4.406

2.  Cost-benefit analysis of universal tandem mass spectrometry for newborn screening.

Authors:  Edgar J Schoen; John C Baker; Christopher J Colby; Trinh T To
Journal:  Pediatrics       Date:  2002-10       Impact factor: 7.124

Review 3.  Neonatal screening for inborn errors of metabolism: cost, yield and outcome.

Authors:  R J Pollitt; A Green; C J McCabe; A Booth; N J Cooper; J V Leonard; J Nicholl; P Nicholson; J R Tunaley; N K Virdi
Journal:  Health Technol Assess       Date:  1997       Impact factor: 4.014

4.  Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria.

Authors:  J Lord; M J Thomason; P Littlejohns; R A Chalmers; M D Bain; G M Addison; A H Wilcox; C A Seymour
Journal:  J Epidemiol Community Health       Date:  1999-03       Impact factor: 3.710

  4 in total
  2 in total

1.  The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.

Authors:  Scott D Grosse; John D Thompson; Yao Ding; Michael Glass
Journal:  Milbank Q       Date:  2016-06       Impact factor: 4.911

2.  The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study.

Authors:  Maria D Karaceper; Pranesh Chakraborty; Doug Coyle; Kumanan Wilson; Jonathan B Kronick; Steven Hawken; Christine Davies; Marni Brownell; Linda Dodds; Annette Feigenbaum; Deshayne B Fell; Scott D Grosse; Astrid Guttmann; Anne-Marie Laberge; Aizeddin Mhanni; Fiona A Miller; John J Mitchell; Meranda Nakhla; Chitra Prasad; Cheryl Rockman-Greenberg; Rebecca Sparkes; Brenda J Wilson; Beth K Potter
Journal:  Orphanet J Rare Dis       Date:  2016-02-03       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.